Nom du produit:Cyclopropanamine, 2-(4-fluorophenyl)-, (1R,2S)- (9CI)

IUPAC Name:(1R,2S)-2-(4-fluorophenyl)cyclopropan-1-amine

CAS:220349-80-4
Formule moléculaire:C9H10FN
Pureté:95%+
Numéro de catalogue:CM433351
Poids moléculaire:151.18

Unité d'emballage Stock disponible Prix($) Quantité
CM433351-1g in stock ȐȐȐƎ

Pour une utilisation en R&D uniquement..

Formulaire de demande

   refresh    

Détails du produit

N° CAS:220349-80-4
Formule moléculaire:C9H10FN
Point de fusion:-
Code SMILES:N[C@@H]1C[C@H]1C1=CC=C(F)C=C1
Densité:
Numéro de catalogue:CM433351
Poids moléculaire:151.18
Point d'ébullition:
N° Mdl:MFCD17010161
Stockage:

Column Infos

Bomedemstat
Merck recently announces the initiation of the pivotal Phase 3 randomized MK-3543-006 clinical trial of Bomedemstat for Essential Thrombocythemia (ET). Lysine-specific demethylase 1 (LSD1) is critical for the regulation of hematopoietic stem and progenitor cells. Bomedemstat is an investigational small molecule irreversible inhibitor of LSD1 by suppressing progenitor cells during blood cell maturation. It is generally well tolerated in ET patients and demonstrates significant clinical activity as a monotherapy.
Bomedemstat has been granted Orphan Drug and Fast Track Designation for the treatment of ET and myelofibrosis (MF) by the U.S. FDA.